<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03148236</url>
  </required_header>
  <id_info>
    <org_study_id>HM20006786</org_study_id>
    <nct_id>NCT03148236</nct_id>
  </id_info>
  <brief_title>Vitamin C in Atrial Fibrillation Ablation</brief_title>
  <acronym>VitC-AF</acronym>
  <official_title>Pilot Study of the Safety and Efficacy of Intravenous Vitamin C in Patients Undergoing Atrial Fibrillation Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-center, double-blinded, randomized, controlled safety and feasibility pilot study of
      high dose IV ascorbic acid (200mg/kg) over 24 hours, divided into four doses and administered
      every six hours with a 30 minute IV infusion time per dose, compared to matched placebo
      infusion
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 18, 2017</start_date>
  <completion_date type="Anticipated">March 13, 2019</completion_date>
  <primary_completion_date type="Actual">March 13, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Creatinine levels</measure>
    <time_frame>baseline, 24 hours (+/- 12 hours), 30 days (+/- 14 days)</time_frame>
    <description>Change in Kidney Function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma levels of ascorbic acid</measure>
    <time_frame>baseline, 24 hours (+/- 12 hours), 30 days (+/- 14 days)</time_frame>
    <description>Change in plasma levels of ascorbic acid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hsCRP</measure>
    <time_frame>baseline, 24 hours (+/- 12 hours), 30 days (+/- 14 days)</time_frame>
    <description>Biomarker of inflammation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Interleukin (IL-6)</measure>
    <time_frame>baseline, 24 hours (+/- 12 hours), 30 days (+/- 14 days)</time_frame>
    <description>Biomarker of inflammation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Von Willebrand Factor (vWF)</measure>
    <time_frame>baseline, 24 hours (+/- 12 hours), 30 days (+/- 14 days)</time_frame>
    <description>Biomarker of blood vessel damage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post Procedural Pain</measure>
    <time_frame>baseline, 24 hours (+/- 12 hours), 30 days (+/- 14 days)</time_frame>
    <description>Difference in pain score between groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Atrial Fibrillation Ablation</condition>
  <arm_group>
    <arm_group_label>Vitamin C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>200mg/kg/day split into 4 doses infused every six hours over 30 minutes in 50ml D5W</description>
    <arm_group_label>Vitamin C</arm_group_label>
    <other_name>Ascorbic Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>50mL infused over 30 minutes</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>D5W</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;/= 21 years

          2. Diagnosis of atrial fibrillation with plans for a catheter-based ablation procedure

          3. Ability to provide informed consent and willingness to be included in the study

        Exclusion Criteria:

          1. Known allergy to Vitamin C

          2. Inability to obtain informed consent

          3. Diabetes mellitus either requiring the use of insulin therapy or not requiring the use
             of insulin therapy but which is uncontrolled, defined as a glycosylated hemoglobin of
             greater than or equal to 8%

          4. Prior catheter-based ablation for atrial fibrillation

          5. Pregnancy or breast feeding

          6. Active renal calculus

          7. Active acute or chronic infection (including HIV or hepatitis C)

          8. Active or recent (within 5 years) malignancy

          9. Autoimmune or autoinflammatory disease

         10. Recent or active use of immunosuppressive medications

         11. Non-English speaking

         12. Ward of the state (inmate, other)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jayanthe Koneru, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2017</study_first_submitted>
  <study_first_submitted_qc>May 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2017</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

